Correction to: Genetics in Medicine; https://doi.org/10.1038/gim.2018.31; published online 15 March 2018
The HTML version of this Article contained errors in Supplementary Figure S2 “Flowchart of the lyso-Gb3 screening and gene analysis in female patients”, which have been detailed in the associated Correction.
The upper square
Female with clinical symptoms suggestive of Fabry disease; “(n = 1036)” was revised to “(n = 1035).”
Neurology; “(n = 227)” was revised to “(n = 226).”
The second square from the top (left side)
Positive lyso-Gb3 screen; “(n = 15)” was revised to “(n = 14).”
Neurology; “(n = 2)” was revised to “(n = 1).”
The third square from the top (second square from the left)
Normal α-Gal A; “(n = 8)” was revised to “(n = 7).”
Neurology; “(n = 1)” was revised to “(n = 0).”
The fourth square from the top (second square from the left)
“Neurology (n = 1)” was deleted.
The revised Supplementary Information can be found as Supplementary Information associated with this Correction.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Maruyama, H., Miyata, K., Mikame, M. et al. Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med 21, 1263 (2019). https://doi.org/10.1038/s41436-019-0447-8
Published:
Issue date:
DOI: https://doi.org/10.1038/s41436-019-0447-8
